PMID- 20235900
OWN - NLM
STAT- MEDLINE
DCOM- 20101214
LR  - 20181201
IS  - 1651-2251 (Electronic)
IS  - 0001-6489 (Linking)
VI  - 130
IP  - 9
DP  - 2010 Sep
TI  - Moxifloxacin in the treatment of acute bacterial rhinosinusitis: results of a 
      multicenter, non-interventional study.
PG  - 1058-64
LID - 10.3109/00016481003629036 [doi]
AB  - CONCLUSION: Moxifloxacin was generally well tolerated and highly effective in the 
      treatment of acute bacterial rhinosinusitis (ABS). The incidence of adverse 
      events (AEs) and adverse drug reactions (ADRs) was low. The effectiveness, 
      safety, and tolerability information collected in this study confirm the clinical 
      safety profile of moxifloxacin and its benefit as a treatment option for ABS. 
      OBJECTIVE: To assess the effectiveness, safety, and tolerability of moxifloxacin 
      under daily life treatment conditions in patients with ABS. METHODS: The study 
      was carried out in China between September 2005 and May 2007. Patients with ABS 
      were treated with moxifloxacin tablets 400 mg once daily for a duration that was 
      left to the physician's discretion. Data were collected on demography, diagnosis 
      of infection, pretreatment, concomitant diseases and medications, moxifloxacin 
      therapy, course of symptoms during investigations, and final assessment of 
      therapy. RESULTS: In all, 578 patients with ABS treated with moxifloxacin were 
      valid for effectiveness analysis. An improvement was observed in 98.8% (n = 
      571/578) of the patients. Cure was documented in 89.4% (n = 517/578) of the 
      patients. The physicians' overall tolerability rating was 'very good' or 'good' 
      in 92.9% (n = 537/578) of patients. The incidence rates of AEs and ADRs were 1.5% 
      (n = 10/681) and 0.6% (n = 4/681), respectively. No serious AE was reported.
FAU - Zhou, Bing
AU  - Zhou B
AD  - ENT Department, Department of Otolaryngology-Head and Neck Surgery, Beijing 
      Tongren Hospital, Capital Medical University, Key laboratory of 
      Otolaryngology-Head and Neck Surgery (Capital Medical University), Ministry of 
      Education, Beijing, China.
FAU - Jiang, Xuejun
AU  - Jiang X
FAU - Zhai, Lijie
AU  - Zhai L
FAU - Xiao, Shuifang
AU  - Xiao S
FAU - Wang, Jiadong
AU  - Wang J
FAU - Xiao, Gensheng
AU  - Xiao G
FAU - Ruan, Biao
AU  - Ruan B
FAU - Liang, Chuanyu
AU  - Liang C
FAU - Ye, Qing
AU  - Ye Q
FAU - Hu, Baohua
AU  - Hu B
FAU - Wang, Haibo
AU  - Wang H
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Acta Otolaryngol
JT  - Acta oto-laryngologica
JID - 0370354
RN  - 0 (Anti-Infective Agents)
RN  - 0 (Aza Compounds)
RN  - 0 (Fluoroquinolones)
RN  - 0 (Quinolines)
RN  - U188XYD42P (Moxifloxacin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Anti-Infective Agents/adverse effects/*therapeutic use
MH  - Aza Compounds/adverse effects/*therapeutic use
MH  - Bacterial Infections/*drug therapy
MH  - Female
MH  - Fluoroquinolones
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Moxifloxacin
MH  - Product Surveillance, Postmarketing
MH  - Prospective Studies
MH  - Quinolines/adverse effects/*therapeutic use
MH  - Rhinitis/*drug therapy
MH  - Sinusitis/*drug therapy
MH  - Treatment Outcome
MH  - Young Adult
EDAT- 2010/03/20 06:00
MHDA- 2010/12/16 06:00
CRDT- 2010/03/19 06:00
PHST- 2010/03/19 06:00 [entrez]
PHST- 2010/03/20 06:00 [pubmed]
PHST- 2010/12/16 06:00 [medline]
AID - 10.3109/00016481003629036 [doi]
PST - ppublish
SO  - Acta Otolaryngol. 2010 Sep;130(9):1058-64. doi: 10.3109/00016481003629036.